NCMP-09. POSTMORTEM STUDY OF ORGAN SPECIFIC TOXICITY IN GLIOBLASTOMA PATIENTS TREATED WITH A COMBINATION OF TEMOZOLOMIDE, BEVACIZUMAB AND IRINOTECAN

MLA

William F Glass, et al. Ncmp-09. Postmortem Study of Organ Specific Toxicity in Glioblastoma Patients Treated with a Combination of Temozolomide, Bevacizumab and Irinotecan. Nov. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2331ea56738b4ad8f256199e6cbab20&authtype=sso&custid=ns315887.

APA

William F Glass, Meenakshi B. Bhattacharjee, L. Maximilian Buja, Mayank Rao, Anil K. Pillai, Julian Wu, Robert L. Hunter, Rongzhen Zhang, Jay-Jiguang Zhu, Nadine Linendoll, Lei Chen, Ping Zhu, Leomar Y. Ballester, Guangrong Lu, Xuejun Tian, & Monika Pilichowska. (2020). Ncmp-09. Postmortem Study of Organ Specific Toxicity in Glioblastoma Patients Treated with a Combination of Temozolomide, Bevacizumab and Irinotecan.

Chicago

William F Glass, Meenakshi B. Bhattacharjee, L. Maximilian Buja, Mayank Rao, Anil K. Pillai, Julian Wu, Robert L. Hunter, et al. 2020. “Ncmp-09. Postmortem Study of Organ Specific Toxicity in Glioblastoma Patients Treated with a Combination of Temozolomide, Bevacizumab and Irinotecan,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2331ea56738b4ad8f256199e6cbab20&authtype=sso&custid=ns315887.